Romain Guièze
A5027678665- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Advanced Breast Cancer Therapies
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Neutropenia and Cancer Infections
- Glycosylation and Glycoproteins Research
- Genetic factors in colorectal cancer
- Cancer-related Molecular Pathways
- Renal Diseases and Glomerulopathies
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- PI3K/AKT/mTOR signaling in cancer
- Calcium signaling and nucleotide metabolism
- Bone and Joint Diseases
- Nanoplatforms for cancer theranostics
- Histone Deacetylase Inhibitors Research
- Cancer Treatment and Pharmacology
- Cutaneous lymphoproliferative disorders research
Centre Hospitalier Universitaire de Clermont-Ferrand
2016-2025
Université Clermont Auvergne
2016-2025
Dana-Farber Cancer Institute
2015-2024
Brigham and Women's Hospital
2015-2024
Harvard University
2015-2024
Dana-Farber Brigham Cancer Center
2015-2024
Broad Institute
2015-2023
University Hospital of Alexandroupolis
2023
University of Perugia
2023
Democritus University of Thrace
2023
In t(8;21)(q22;q22) acute myeloid leukemia, the prognostic value of early minimal residual disease assessed with real-time quantitative polymerase chain reaction is most important factor, but how long-term monitoring may contribute to drive individual patient decisions remains poorly investigated. multicenter CBF-2006 study, a prospective peripheral blood and bone marrow samples was performed every 3 months year, respectively, for 2 years following intensive chemotherapy in 94 patients first...
The BCL-2 inhibitor venetoclax is effective in chronic lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid malignancies such as diffuse large B-cell lymphoma (DLBCL) are frequently intrinsically resistant to venetoclax. Although genomic mechanisms mutations have been described, this likely only explains a subset of cases. Using two complementary functional precision medicine techniques -- BH3-profiling and high throughput-kinase activity mapping we found...
Historically, double or triple hit lymphoma (DHL and THL) have poor outcomes with conventional chemotherapy, but there is currently no guideline. We report the French experience in managing DHL THL first line using collective data on both survival tolerance. All consecutive patients newly diagnosis of large B-cell MYC, BCL2, and/or BCL6 rearrangements, as determined by FISH between January 2013 April 2019 were included. Based eligibility criteria, 160 selected among 184 identified. With a...
Not available.
Abstract Acquired resistance to Bcl-2 inhibitor, venetoclax, poses a therapeutic challenge in the management of chronic lymphocytic leukemia (CLL) and acute myeloid (AML). Venetoclax-resistant cells exhibit increased accumulation Mcl-1, thereby switching dependence from Mcl-1. However, mechanism behind Mcl-1 upon acquisition venetoclax remains elusive. Given that change cellular redox state affects cell survival drug sensitivity, we sought investigate interplay between venetoclax-resistant...